FDA Sets Decision Date for Subcutaneous Leqembi (Leqembi IQLIK) on May 24, 2026
The U.S. Food and Drug Administration (FDA) has accepted for priority review the application for Leqembi IQLIK (lecanemab) for subcutaneous administration in early Alzheimer's disease. A decision on the expanded indication is expected soon, simplifying treatment for patients by transitioning from intravenous infusions to an autoinjector.
A Shot Instead of an IV: Why the FDA's Decision Delay on Leqembi IQLIK Is Not a Setback but a Strategic Move
The Bottom Line: What's Really Happening
May 24, 2026 — the date the industry awaited as the moment of truth for subcutaneous lecanemab. However, on May 7-8, the FDA officially notified Eisai and Biogen that the decision is postponed to August 24, 2026. The regulator classified the companies' additional materials as a "major amendment," automatically adding three months to the standard review timeline.
Superficial view: bureaucratic delay. Reality: the FDA gave the green light but isn't saying it out loud yet. The phrasing "no approvability concerns raised" is not standard courtesy but a signal to the market. The regulator is essentially saying: the drug will be approved; we just need time to digest the technical details.
Why does this matter? Leqembi IQLIK is the first and only anti-amyloid therapy aiming for fully at-home use: both initiation and maintenance phases via autoinjector. Currently, patients must travel to a clinic for IV infusions every two weeks for 18 months. Approval of the sBLA would remove this barrier. This is not just convenience — it's a shift in the Alzheimer's treatment model from hospital-based to home-based care.
Timeline and Context
The story unfolded rapidly. In August 2025, the FDA approved Leqembi IQLIK 360 mg for maintenance therapy — but only after 18 months of IV induction. This was a half-step: patients were still tied to an IV at the start. In January 2026, Eisai and Biogen submitted an sBLA to eliminate the IV phase entirely, and the FDA granted Priority Review with a decision date of May 24.
Now — a delay to August. Importantly, the Priority Review status remains. The application is still prioritized, and the regulator did not request new clinical data. The "additional information" likely pertains to manufacturing documentation for the autoinjector and drug stability during home storage. For the FDA, burned by Aduhelm, extra caution with biotech drugs has become standard practice.
Market context: Leqembi is already approved in 53 countries and under review in seven more. Analysts estimate sales could reach $1.6–1.8 billion by 2027. Competitors are not idle — Eli Lilly's donanemab is hot on its heels in the U.S.
Winners and Losers
Winners:
- Eisai and Biogen — but not immediately. The three-month delay is inconvenient for quarterly reports, but strategically it allows accumulation of more real-world data on the maintenance form. Recent analysis shows 78.4% of patients remain on therapy at 18 months and 67.3% at 24 months. This is a strong argument for expanded indication. Additionally, the companies gain time to prepare commercial infrastructure — training medical staff, setting up home patient support services, and logistics for autoinjector delivery.
- Patients and their families. Each month of waiting means thousands of elderly people forced to travel to clinics for two-hour infusions. But once approval comes, the transition will be swift: the drug is already on the market, pharmacy networks are ready, and insurance codes are assigned. For a family where one spouse cares for a dementia patient, eliminating 26 annual hospital visits means reclaiming hundreds of hours of life.
- Eli Lilly — tactically. Donanemab remains the only competitor with an alternative dosing regimen. The extra three months give Lilly a window to expand market share without a subcutaneous competitor.
Losers:
- Investors betting on the May catalyst. The delay news pressures Biogen (NASDAQ: BIIB) shares in the short term. Eisai trades in Tokyo and is less prone to speculative swings, but short-term disappointment is inevitable. Option volumes betting on a May decision were significant.
- Infusion centers. The IV infusion business is worth billions. Every patient switching to a home autoinjector drops out of the client pool. The 18-month IV phase guaranteed a steady stream. If the initiation phase also goes subcutaneous, infusion centers lose patients from day one of therapy. This is especially painful for small regional clinics where Alzheimer's constituted a significant share of the "infusion portfolio."
- Insurers — paradoxically. Leqembi IQLIK could save up to $72,891 per patient over four years by eliminating infusion administration costs. But in the short term, insurance companies would prefer the status quo: their actuarial models are already set for the current fiscal year, and any changes create reserve uncertainty.
What the Media Isn't Saying
The first non-obvious insight is economic, concerning not so much Leqembi itself but the structure of Medicare spending. Currently, the system pays not only for the drug but also for its administration — infusion services. Switching to a home autoinjector saves on administration but loses control over tracking. A home injection is not documented as rigorously as a hospital procedure. This creates an adherence tracking problem: how will Medicare ensure the patient is actually injecting weekly? In clinical trials, this was monitored, but in real-world practice, an elderly patient might miss doses. The FDA is likely discussing this aspect in the additional materials.
The second point is competitive dynamics. The delay to August 2026 coincides with a potential window for donanemab. Lilly plans to expand indications and has its own subcutaneous protocol. If the FDA accelerates donanemab's review, Eisai and Biogen could lose first-mover advantage. This is not just a drug race — it's a battle of two business models: Eisai bets on a fully home-based path, Lilly on flexibility with physician oversight.
The third unspoken aspect is the Japanese context. Eisai is a Japanese company, and its domestic market is critical. In Japan, Leqembi is also undergoing approval for the subcutaneous form. The FDA's decision will signal to Japan's regulator PMDA. If the FDA approves in August, PMDA will likely decide by end of 2026. Japan is the second-largest Alzheimer's drug market globally after the U.S., so synchronizing regulatory decisions is part of Eisai's strategy.
Forecast: Next 30 Days and 90 Days
30 days (by June 9, 2026):
- Eisai will report quarterly earnings for the period ending May 2026. The company is expected to reaffirm its Leqembi forecast — about 42.5 billion yen for the current fiscal year. Special attention will be on management comments about the PDUFA date delay. Most likely, they will say "confident in approval" without specific promises.
- Biogen (BIIB) shares will either dip slightly or stay range-bound — the market has already priced in the delay. A negative factor could be a downgrade by an investment bank, but that's unlikely given the lack of approvability issues.
- Competitors, especially Eli Lilly, will ramp up marketing efforts, using the three-month window to "intercept" patients choosing therapy.
90 days (by August 7, 2026):
- The FDA will approve Leqembi IQLIK 500 mg for initiation therapy. This is not a prediction — it's almost a certainty given the Priority Review status and no signals of problems. The decision will come a few days before August 24, as the FDA often announces verdicts ahead of the official PDUFA date.
- Within 24-48 hours of approval, Eisai and Biogen will announce commercial launch readiness. Autoinjectors will be available in U.S. retail pharmacies within 2-3 weeks. The price will not differ significantly from the IV form — regulatory pricing requirements for biotech drugs limit flexibility.
- A patient shift from IV to subcutaneous will begin. Estimates suggest up to 70% of U.S. patients will prefer the home option — roughly 8,000-10,000 people in the first months after approval.
- Eli Lilly will likely accelerate its own subcutaneous donanemab application to narrow the competitor's lead. Expected submission: fall 2026, decision: spring 2027.
Fundamental takeaway: The PDUFA date delay is not a bureaucratic glitch or a warning sign. It is the measured pace of a regulator that sees approval as inevitable and simply gives itself time to polish details. Leqembi IQLIK will become the first Alzheimer's drug with a fully home-based administration route — and this will change not only the dementia therapy market but also the infrastructure of care delivery. The next 90 days are the final chapter of waiting before one of humanity's most burdensome diseases begins to be treated at home, with a fifteen-second injection.
— Editorial Team
